Democratic senators introduce registry legislation

Share this article:
A group of Democratic senators has introduced a bill that would require drug makers and medical device manufacturers to register clinical trials of their products in a public database at their onset and report subsequent test results. The legislation would require registration before clinical trials involving patients could be conducted.
Several drug companies have already indicated they will start posting trial results on company Web sites, a perceived reaction to mounting pressure from medical editors who say they will not publish papers on clinical trial results unless they have been publicly accessible since trial outset. The American Medical Association also has passed a resolution calling for a similar national database.
It is unlikely that action on the bill would be taken until after the presidential election. Sponsors of the bill included Senators Edward Kennedy of Massachusetts, Christopher Dodd of Connecticut, Tim Johnson of South Dakota and Ron Wyden of Oregon.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...